B+
Bull case
20%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
AMPH
AmphastarCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$17.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.3
Score
AI commentary
The T3 follow-up confirms a modest Q2 beat and an initially positive price response, but the earnings mix was uneven and no post-print analyst revisions were available. Social coverage was absent, and low analyst coverage plus loose peers reduce confidence in a stronger directional thesis. Sentiment is cautiously positive but best treated as monitoring-oriented.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 2026 results modestly exceeded pre-release expectationsMedium impact
Amphastar reported Q2 revenue of $183.9 million and GAAP EPS of $0.67, versus stored pre-release Zacks estimates of $181.94 million and $0.66; adjusted EPS was $0.91. Management cited revenue growth, gross-margin expansion, new-product launches, and pipeline progress, while also flagging pricing and competitive pressure [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-30].
2026-08-15catalystPost-earnings digestion of commercial mixMedium impact
Near-term sentiment depends on whether the modest earnings beat and 50.8% gross margin offset weakness in BAQSIMI pricing, glucagon, and epinephrine. The latest market feed showed AMPH at $20.78, up approximately 4.8% versus the prior close, but attribution of the move to earnings is unconfirmed.
2026-12-31catalystCommercial uptake from recently launched productsHigh impact
Ipratropium bromide generated $8.4 million after its April 2026 launch, while iron sucrose and teriparatide contributed year-over-year growth and albuterol volumes continued to improve. Sustained uptake could help offset legacy-product erosion, but competition and pricing remain material constraints [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology